Last reviewed · How we verify

NCT06118671

The Evaluation of Artificial Intelligence in Lifestyle Management of Diabetic Patients in Community

Status unknown NA Last updated 7 November 2023
What this trial tests

NA trial testing personalized lifestyle intervention by AI in Diabetes in 460 participants. Status unknown.

Timeline
7 November 2023
Primary endpoint
7 November 2024
7 November 2024

Quick facts

Lead sponsorChongqing Medical University
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposeother
Enrollment460
Start date7 November 2023
Primary completion7 November 2024
Estimated completion7 November 2024
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Chongqing Medical University

Who can join

Adults 18 to 80, any sex, with Diabetes. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical trial is to learn about the application and effectiveness evaluation of artificial intelligence (AI) in lifestyle management of diabetic patients in community.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Assessment of priorities, quality, and inclusivity of digital therapeutics trials in China.
    Wang Z, Xia X, Lu W, Ye Y, et al · · 2025 · cited 1× · PMID 39910261 · DOI 10.1038/s41746-025-01477-6

Verify or expand the search:

Other recruiting trials for Diabetes

Currently open trials in the same condition.

Other Chongqing Medical University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06118671.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing